uniQure Inc.: uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B

~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the

Related Keywords

United Kingdom ,Massachusetts ,United States ,Amsterdam ,Noord Holland ,Netherlands ,Frankfurt ,Brandenburg ,Germany ,Dennis Riedl ,Chiara Russo ,Wolfgang Miesbach ,Mariae Cantor ,Matt Kapusta ,Tom Malone ,Care Center ,University Hospital Of Frankfurt ,European Union ,European Commission ,Regulatory Agency ,European Economic Area ,Bill Mezzanotte ,Professor Wolfgang Miesbach ,Comprehensive Care Center ,University Hospital ,Drug Administration ,Annual Bleeding Rate ,Qure Forward Looking ,License Agreement ,Annual Report ,Qure Contacts ,Uniqure ,Nnounces ,European ,Commission ,Approval ,First ,Gene ,Therapy ,Adults ,Hemophilia ,